

1F00\$



ABX-PF1 DIV2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group Art Unit : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/776,649
Confirmation No. : 5045
Filed : February 10, 2004
For : METHODS AND HOST CELLS FOR PRODUCING
HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York
July 19, 2006

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT


Sir:

Transmitted herewith is a Supplemental Information Disclosure Statement in the above-identified patent application. This Statement is being submitted after the period specified in 37 C.F.R. § 1.97(c) and before payment of the issue fee.

Pursuant to 37 C.F.R. § 1.97(d), the Director is hereby authorized to charge payment of the \$180.00 for filing this Statement to Deposit Account No. 06-1075, Order No. 000659-0030. The Director is hereby also authorized to charge payment of

any additional fees required in connection with this Statement to Deposit Account
No. 06-1075, Order No. 000659-0030. A duplicate copy of this Transmittal Letter is
enclosed herewith.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)

Margaret A. Pierri (Reg. No. 30,709)

Attorneys for Applicants

c/o FISH & NEAVE IP GROUP

ROPES & GRAY LLP

Customer No. 1473

1251 Avenue of the Americas


New York, New York 10020-1105

Tel.: (212) 596-9000

Fax.: (212) 596-9090

I hereby certify that this correspondence
is being deposited with the US Postal Service
as First Class Mail in an envelope Addressed to:
Commissioner for Patents
P.O. Box 1450

Alexandria, VA 22313-1450 on

July 19, 2006


Signature of person Signing



ABX-PF1 DIV2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski
Group Art Unit : 1644
Applicants : Douglas Charles Hanson et al.
Application No. : 10/776,649
Confirmation No. : 5045
Filed : February 10, 2004
For : METHODS AND HOST CELLS FOR PRODUCING HUMAN
MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York
July 19, 2006

Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.56 AND 1.97

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make the following
documents of record in the above-identified patent application¹:

¹ For the Examiner's convenience, applicants have also enclosed (in duplicate) a completed Form PTO/SB/08A, listing these documents.

OTHER DOCUMENTS

Karandikar et al., "CTLA-4: A Negative Regulator of Autoimmune Disease," *J. Exp. Med.*, 184:783-788 (1996)

Rudikoff et al., "Single Amino Acid Substitution Altering Antigen-Binding Specificity," *Proc. Natl. Acad. Sci. USA*, 79:1979-1983 (1982).


REMARKS

Pursuant to 37 C.F.R. § 1.97(d)(1), the undersigned hereby certifies that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

It is respectfully requested that this documents be (1) fully considered by the Patent and Trademark Office during examination of this application, and (2) printed on any patent which may issue on this application. Applicants request that a copy of Form PTO/SB/08A, as considered and initialed by the Examiner, be returned with the next communication.

In the Transmittal Letter accompanying this Statement, applicants have authorized payment of the fee set forth in 37 C.F.R. § 1.17(p).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Margaret A. Pierri', is written over a horizontal line.

Jane T. Gunnison (Reg. No. 38,479)

Margaret A. Pierri (Reg. No. 30,709)

Attorneys for Applicants

c/o FISH & NEAVE IP GROUP

ROPES & GRAY LLP


Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1105

Tel.: (212) 596-9000

Fax.: (212) 596-9090



Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
We are required to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known	
				Application Number	10/776,649
				Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Ilia I. Ouspenski
				Attorney Docket Number	ABX-PF1 DIV2
Sheet	1	of	1		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**